


- 47 -

## CLAIMS

1. A compound in accord with structural diagram I:



I

5 wherein:

$R^1$  at each occurrence is independently selected from CN,  $CF_3$ ,  $OCF_3$ ,  $OCHF_2$ , halogen,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkynyl,  $R^a$ ,  $R^b$ ,  $SR^a$ ,  $NR^aR^b$ ,  $CH_2NR^aR^b$ ,  $OR^a$  or  $CH_2OR^a$ , where  $R^a$  and  $R^b$  are independently at each occurrence hydrogen,  $C_{1-6}$ alkyl,  $C(O)R^c$ ,  $C(O)NHR^c$  or  $CO_2R^c$ , where  $R^c$  at  
 10 each occurrence is  $C_{1-6}$ alkyl; or,  $R^a$  and  $R^b$  together are  $(CH_2)_jG(CH_2)_k$  or  $G(CH_2)_jG$ , where G is oxygen or sulfur, j is 1, 2, 3 or 4, and k is 0, 1 or 2;

m is 1, 2 or 3 where at least one  $R^1$  moiety is other than hydrogen;

$R^2$  and  $R^3$  are independently hydrogen,  $C_{1-6}$ alkyl or  $C_{1-6}$ alkyl substituted with  $C_{1-4}$ alkoxy;

$R^4$  at each occurrence is independently selected from hydrogen, CN,  $CF_3$ ,  $OCF_3$ ,  $OCHF_2$ ,  
 15 halogen,  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkynyl,  $SR^a$ ,  $NR^aR^b$ ,  $CH_2NR^aR^b$ ,  $OR^a$  or  $CH_2OR^a$ , where  $R^a$  and  $R^b$  are independently at each occurrence hydrogen,  $C_{1-6}$ alkyl,  $C(O)R^c$ ,  $C(O)NHR^c$  or  $CO_2R^c$  where  $R^c$  at each occurrence is  $C_{1-6}$ alkyl; or,  $R^a$  and  $R^b$  together are  $(CH_2)_jG(CH_2)_k$  or  $G(CH_2)_jG$ , and

n is 0, 1, 2 or 3;

20 in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

2. A compound according to Claim 1, wherein:

$R^1$  independently at each occurrence is CN,  $C_{1-6}$ alkyl or  $OR^c$  and m is 1, 2 or 3;

$R^2$  and  $R^3$  are independently hydrogen or  $C_{1-6}$ alkyl, and

25  $R^4$  independently at each occurrence is halogen where n is 1 or 2;

in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

- 48 -

3. A compound according to Claim 1 wherein:


$R^1$  independently at each occurrence is CN, ethyl or methoxy and m is 1, 2 or 3;

$R^2$  and  $R^3$  are independently hydrogen or methyl, and

$R^4$  independently at each occurrence is halogen where n is 1 or 2;

5 in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

4. A compound according to Claim 1, according to structural diagram II



II

10 wherein  $Ar$  is selected from phenyl, 3,4-dichlorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 4-difluoromethoxyphenyl or 4-trifluoromethoxyphenyl;

$R^1$  is selected from H, methyl, ethyl or methoxy where m is 1 or 2, and

$R^2$  and  $R^3$  are independently is selected from H or methyl, and

15 in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

5. A pharmaceutically-acceptable salts of a compound according to Claim 1 made with an inorganic or organic acid which affords a physiologically-acceptable anion.

20 6. A pharmaceutically-acceptable salts of a compound according to Claim 5, wherein said inorganic or organic acid is selected from hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, sulfamic, para-toluenesulfonic, acetic, citric, lactic, tartaric, malonic, fumaric, ethanesulfonic, benzenesulfonic, cyclohexylsulfamic, salicylic and quinic acids.

25 7. A pharmaceutical composition comprising a compound according to Claim 1, an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable carrier.

- 49 -

8. A method of treating a disease condition wherein antagonism of NK<sub>1</sub> receptors in combination with SRI activity is beneficial which method comprises administering to a warm-blooded animal an effective amount of a compound according to Claim 1 or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof.

9. The use of a compound according to Claim 1 or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof in the preparation of a medicament for use in a disease condition wherein antagonism of the NK<sub>1</sub> receptors and SRI activity is beneficial.

10

10. A method for treating a disorder or condition selected from hypertension, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, post partum depression, generalized anxiety disorder, agoraphobia, social phobia, simple phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, anorexia nervosa, bulimia nervosa, obesity, addictions to alcohol, cocaine, heroin, phenobarbital, nicotine or benzodiazepines; cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, dementia, amnestic disorders, age-related cognitive decline, dementia in Parkinson's disease, neuroleptic-induced parkinsonism, tardive dyskinesias, hyperprolactinaemia, vasospasm, cerebral vasculature vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder, chronic paroxysmal hemicrania and headache associated with vascular disorders in a mammal, comprising administering an effective amount of a compound according to Claim 1 or a pharmaceutically-acceptable salt thereof effective in treating such disorder or condition and a pharmaceutically-acceptable carrier.

11. The use of a compound according to Claim 1, for the preparation of a medicament useful for the treatment of hypertension, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression,

30

- 50 -

depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, post partum depression, generalized anxiety disorder, agoraphobia, social phobia, simple phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, anorexia nervosa, bulimia nervosa, obesity, 5 addictions to alcohol, cocaine, heroin, phenobarbital, nicotine or benzodiazepines; cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, dementia, amnesic disorders, age-related cognitive decline, dementia in Parkinson's disease, neuroleptic-induced parkinsonism, tardive dyskinesias, hyperprolactinaemia, vasospasm, cerebral vasculature vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of 10 schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder, chronic paroxysmal hemicrania and headache associated with vascular disorders in a mammal.